Clinical Trials Logo

Treatment clinical trials

View clinical trials related to Treatment.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06315582 Recruiting - Treatment Clinical Trials

Surgical Approach to Uterine Septum

Start date: March 11, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to determine if the use of scissors without electrosurgery is superior to bipolar electrosurgery for resection of uterine septum. The investigators will be comparing procedure-level variables such as operative time, complications, and need for additional procedures.

NCT ID: NCT06281327 Recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

Start date: March 2024
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.

NCT ID: NCT06233539 Recruiting - Treatment Clinical Trials

A Study on Diagnosis and Treatment Strategies for Atlantoaxial Dislocation

Start date: December 1, 2022
Phase:
Study type: Observational [Patient Registry]

The most effective treatment for atlantoaxial dislocation is surgical treatment, with the principle of achieving reduction, reconstruction, and fusion of the atlantoaxial joint. The surgical strategies mainly include simple anterior approach, simple posterior approach, and combined anterior posterior approach. The investigators have summarized 904 cases of atlantoaxial instability or dislocation from 1998 to 2010 and preliminarily published the diagnosis and treatment strategy tree of the Third Hospital of Beijing Medical University. This strategy is divided into four types based on the severity of atlantoaxial dislocation: unstable, reversible, difficult to recover, and skeletal, and enters different surgical treatment processes. With the increase in the number of cases, accumulation of experience, and technological improvements in the past decade, spinal surgery colleagues have updated their classification diagnosis, diagnosis and treatment processes, and surgical techniques for atlantoaxial instability or dislocation. However, the selection of treatment strategies for atlantoaxial dislocation is mostly based on the surgeon's own experience, and there is a lack of standardized, large-scale, and high-level evidence-based medical research on the safety and effectiveness of current empirical strategies. Based on this, this study intends to adopt a multicenter, retrospective, and prospective study to construct a high-quality clinical cohort of atlantoaxial dislocation, update the classification and diagnosis and treatment strategies of atlantoaxial dislocation. And conduct long-term follow-up on patients to evaluate their safety and effectiveness, guide the surgical treatment of atlantoaxial dislocation, and thus form a recognized diagnostic and treatment standard for atlantoaxial dislocation.

NCT ID: NCT06199089 Recruiting - Clinical trials for Immune Thrombocytopenia

A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Start date: January 16, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of CM313 in the treatment of immune thrombocytopenia in patients who have failed glucocorticoid therapy.

NCT ID: NCT06168851 Recruiting - Clinical trials for Immune Thrombocytopenia

Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)

Start date: December 28, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

NCT ID: NCT06118502 Recruiting - Cigarette Smoking Clinical Trials

A Clinical Trial of Adaptive Treatment for Early Smoking Cessation Relapse

ADAPT
Start date: March 25, 2024
Phase: N/A
Study type: Interventional

This is a research study to find out if treatment decision making can be improved for smokers who find it difficult to quit with medications. Everyone who participates in this study will receive free product, either nicotine replacement therapies (patches and lozenges), varenicline, or a harm reduction product (e-cigarette) for a full 12 weeks. Most participants will receive some combination of these treatments, depending on individual response to each. All visits and study assessments will be entirely remote. All treatments will be provided free of charge for the first 12 weeks. After that, the study team will contact the participants 6 months after the first study phone call to complete another survey. The study lasts six months and will involve 8 surveys.

NCT ID: NCT06094881 Recruiting - Clinical trials for Immune Thrombocytopenia

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)

Start date: December 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.

NCT ID: NCT06020560 Recruiting - Clinical trials for Venous Thromboembolism

Study of Low Molecular Weight Heparins

DANHEP
Start date: March 23, 2023
Phase: Phase 4
Study type: Interventional

DANHEP is a cluster randomized study of two different low molecular weight heparins. Parenteral anticoagulants are used in a variety of settings, including treatment and prevention of venous thromboembolism in cancer patients, medical patients, and surgical patients, along with the use as adjuvant therapy for coronary syndromes. The most frequently used parenteral anticoagulants in Denmark, include the two different low molecular weight heparins; dalteparin and tinzaparin. The two drugs are considered equally efficient and safe regarding treatment and prevention of thrombosis and risk of bleeding. Importantly, there is a lack of evidence regarding whether these drugs are in fact comparable. The aim of this study is therefore to investigate the comparative safety and efficacy of the two different low molecular weight heparins (dalteparin and tinzaparin using cluster randomization in patients with an indication for low molecular weight heparins.

NCT ID: NCT06014775 Recruiting - Treatment Clinical Trials

Anti-CD38 Antibody Treating Evans Syndrome

2023-D-ES
Start date: December 2023
Phase: Phase 2
Study type: Interventional

A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

NCT ID: NCT05995054 Recruiting - Clinical trials for Immune Thrombocytopenia

A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia

2023CD20ITP
Start date: August 28, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Obinutuzumab in the treatment of immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment.